WITHUS PHARMACEUTICAL Co.,LTD. (KOSDAQ: 330350)
South Korea
· Delayed Price · Currency is KRW 6,310.00
+90.00 (1.45%)
Nov 15, 2024, 9:00 AM KST
WITHUS PHARMACEUTICAL Co.,LTD. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Operating Revenue | 98,274 | 80,119 | 64,680 | 57,419 | 53,406 | 52,393 | Upgrade
|
| Other Revenue | - | -0 | - | - | -0 | - | Upgrade
|
| Revenue | 98,274 | 80,119 | 64,680 | 57,419 | 53,406 | 52,393 | Upgrade
|
| Revenue Growth (YoY) | 49.37% | 23.87% | 12.65% | 7.51% | 1.93% | 1.28% | Upgrade
|
| Cost of Revenue | 36,121 | 31,481 | 26,345 | 23,894 | 21,076 | 19,426 | Upgrade
|
| Gross Profit | 62,153 | 48,638 | 38,335 | 33,525 | 32,330 | 32,967 | Upgrade
|
| Selling, General & Admin | 49,826 | 37,237 | 29,767 | 26,100 | 22,699 | 20,887 | Upgrade
|
| Research & Development | 2,084 | 1,868 | 2,357 | 1,420 | 1,807 | 1,512 | Upgrade
|
| Other Operating Expenses | 190.87 | 186.67 | 278.07 | 296.44 | 202.68 | 236.27 | Upgrade
|
| Operating Expenses | 53,512 | 40,729 | 33,457 | 28,639 | 25,100 | 23,232 | Upgrade
|
| Operating Income | 8,641 | 7,909 | 4,878 | 4,886 | 7,230 | 9,735 | Upgrade
|
| Interest Expense | -784.34 | -596.06 | -390.74 | -323.96 | -229.23 | -367.66 | Upgrade
|
| Interest & Investment Income | 584.78 | 727.19 | 468.62 | 392.66 | 464.09 | 791.74 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.7 | 1.72 | 0.63 | -3.98 | 6.57 | -12.21 | Upgrade
|
| Other Non Operating Income (Expenses) | -570.93 | -425.51 | -435.03 | -305.14 | -235.98 | -252.97 | Upgrade
|
| EBT Excluding Unusual Items | 7,873 | 7,617 | 4,521 | 4,646 | 7,236 | 9,894 | Upgrade
|
| Gain (Loss) on Sale of Investments | 771.14 | 1,515 | -373.86 | 979.32 | 520.11 | 141.82 | Upgrade
|
| Gain (Loss) on Sale of Assets | 4.54 | 9.04 | 10.78 | -385 | 5.13 | - | Upgrade
|
| Pretax Income | 8,649 | 9,141 | 4,158 | 5,240 | 7,761 | 10,036 | Upgrade
|
| Income Tax Expense | 996.92 | 1,182 | 1,679 | 976.07 | 1,109 | 1,997 | Upgrade
|
| Net Income | 7,652 | 7,959 | 2,479 | 4,264 | 6,652 | 8,039 | Upgrade
|
| Net Income to Common | 7,652 | 7,959 | 2,479 | 4,264 | 6,652 | 8,039 | Upgrade
|
| Net Income Growth | 376.48% | 221.04% | -41.86% | -35.90% | -17.25% | -7.19% | Upgrade
|
| Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 8 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 8 | 8 | Upgrade
|
| Shares Change (YoY) | 0.20% | 0.03% | -0.10% | 59.55% | 6.63% | 0.15% | Upgrade
|
| EPS (Basic) | 579.49 | 603.41 | 188.00 | 323.00 | 804.02 | 1036.00 | Upgrade
|
| EPS (Diluted) | 579.49 | 603.41 | 188.00 | 323.00 | 804.02 | 1036.00 | Upgrade
|
| EPS Growth | 375.54% | 220.96% | -41.80% | -59.83% | -22.39% | -7.33% | Upgrade
|
| Free Cash Flow | -7,257 | -12,044 | -9,952 | 1,354 | -4,455 | 3,256 | Upgrade
|
| Free Cash Flow Per Share | -549.56 | -913.07 | -754.70 | 102.59 | -538.39 | 419.66 | Upgrade
|
| Gross Margin | 63.24% | 60.71% | 59.27% | 58.39% | 60.54% | 62.92% | Upgrade
|
| Operating Margin | 8.79% | 9.87% | 7.54% | 8.51% | 13.54% | 18.58% | Upgrade
|
| Profit Margin | 7.79% | 9.93% | 3.83% | 7.43% | 12.46% | 15.34% | Upgrade
|
| Free Cash Flow Margin | -7.38% | -15.03% | -15.39% | 2.36% | -8.34% | 6.22% | Upgrade
|
| EBITDA | 12,121 | 10,754 | 6,826 | 6,387 | 9,207 | 11,150 | Upgrade
|
| EBITDA Margin | 12.33% | 13.42% | 10.55% | 11.12% | 17.24% | 21.28% | Upgrade
|
| D&A For EBITDA | 3,480 | 2,844 | 1,948 | 1,501 | 1,977 | 1,415 | Upgrade
|
| EBIT | 8,641 | 7,909 | 4,878 | 4,886 | 7,230 | 9,735 | Upgrade
|
| EBIT Margin | 8.79% | 9.87% | 7.54% | 8.51% | 13.54% | 18.58% | Upgrade
|
| Effective Tax Rate | 11.53% | 12.93% | 40.38% | 18.63% | 14.29% | 19.90% | Upgrade
|
| Advertising Expenses | - | 841.87 | 831.45 | 887 | - | 802 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.